Company highlights 2023 plan as it progresses towards IND submittal and Ovarian Cancer
Treatments
EDINBURGH, Scotland, April 26, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company today laid out a fundamental shift in the ongoing development and manufacture of its lead product TCB-008, an allogeneic gamma-delta T cell therapies for cancer, and the Company's CAR modified gamma-delta T cell.
Read more at prnewswire.com